09-08-2018
alexandrumagurean / iStockphoto.com
A proposed change to supplementary protection certificate (SPC) rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association (IPHA).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
SPCs, supplementary protection certificates, patent, generics, Irish Pharmaceutical Healthcare Association, IPHA, The Irish Times, European Commission, EU
